Ultragenyx resubmits gene therapy for rare neuro disease to FDAnews2026-01-30T16:50:40+00:00January 30th, 2026|Endpoints News|
FDA suspends two Regenxbio gene therapy trials after patient developed brain tumornews2026-01-28T15:56:29+00:00January 28th, 2026|Endpoints News|
Cellares raises $257M to fund global expansion as it eyes 2027 IPOnews2026-01-28T12:00:48+00:00January 28th, 2026|Endpoints News|
Lilly partners with recombinase-based gene editing startup Seamless Therapeuticsnews2026-01-28T12:00:19+00:00January 28th, 2026|Endpoints News|
FDA greenlights Life Biosciences’ gene therapy study to rewind the age of cellsnews2026-01-27T13:00:47+00:00January 27th, 2026|Endpoints News|
Sarepta touts three-year Duchenne gene therapy data after patient deathsnews2026-01-26T16:17:47+00:00January 26th, 2026|Endpoints News|
ImmunityBio’s cell therapy posts encouraging early data in rare blood cancernews2026-01-16T16:05:02+00:00January 16th, 2026|Endpoints News|
Ocugen touts Phase 2 data for eye disease gene therapynews2026-01-15T13:15:39+00:00January 15th, 2026|Endpoints News|
Scribe Therapeutics plans to test cholesterol-lowering therapy this summernews2026-01-14T21:11:18+00:00January 14th, 2026|Endpoints News|
Nvidia-partnered startup reveals AI-generated enzymes for precise gene insertionnews2026-01-12T21:18:10+00:00January 12th, 2026|Endpoints News|
